Summit Therapeutics Inc. Stock

Stocks

SMMT

US86627T1088

Biotechnology & Medical Research

Market Closed - 04:00:00 2026-09-25 pm EDT 5-day change 1st Jan Change
15.61 USD -4.70% Intraday chart for Summit Therapeutics Inc. -12.55% -10.75%

Valuation: Summit Therapeutics Inc.

Market Cap 9.41B 12.45B 10.93B 10.32B 17.61B 1,194B 17.73B 124B 47.83B 610B 46.76B 45.74B 1,960B P/E 2026 *
-13.6x
P/E 2027 * -13.6x
Enterprise Value 8.94B 11.83B 10.38B 9.8B 16.73B 1,134B 16.85B 117B 45.44B 579B 44.42B 43.46B 1,862B EV / Sales 2026 *
3,053x
EV / Sales 2027 * 221x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
Sep. 22 Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026 CI
Sep. 15 Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients CI
Sep. 14 Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit MT
Sep. 09 Summit Therapeutics Shares Rise After Upgrade From Jefferies MT
Sep. 09 Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15 MT
Aug. 26 Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release MT
Aug. 26 US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results MT
Aug. 26 Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints MT
Aug. 26 Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer CI
Aug. 25 Wall Street Wants Receipts Zonebourse
Aug. 25 Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines… Zonebourse
Aug. 12 Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC MT
Aug. 12 Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12 MT
1 day-4.70%
1 week-12.55%
Current month+14.61%
1 month+16.84%
3 months+10.08%
6 months-12.99%
Current year-10.75%
1 week 15.55
Extreme 15.55
18.42
1 month 13.37
Extreme 13.37
18.83
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.64
Extreme 1.64
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 2022-07-24
Chief Executive Officer 81 2020-03-31
Director of Finance/CFO 48 2024-04-01
Director TitleAgeSince
Chairman 81 2020-01-31
Director/Board Member 48 2019-11-30
Director/Board Member 55 2020-11-10
Date Insider Type Main position Quantity % Market Cap. Importance
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Executive Officer

100,000 0.0129%
6/4/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
-4.70%-12.55%-22.95%+713.02% 12.45B
-3.30%+1.50%+51.24%+99.26% 72.26B
+1.25%-3.01%+40.12%+77.12% 60.24B
+2.12%+5.26%+32.50%+21.28% 27.73B
-3.06%-1.81%-13.10%+357.06% 25.74B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+22.91%-9.68% 20.74B
-1.70%-2.12%+146.86%+314.52% 15.06B
+0.36%-0.34%+50.32%+166.42% 14.42B
+0.21%+1.17%-8.07%+499.10% 14.23B
Average -0.92%-1.21%+30.03%+223.36% 28.76B
Weighted average by Cap. -0.94%-0.56%+33.75%+154.39%

Financials

2026 *2027 *
Net sales 2.93M 3.87M 3.4M 3.21M 5.48M 371M 5.52M 38.43M 14.88M 190M 14.55M 14.23M 610M 41.74M 55.26M 48.49M 45.8M 78.13M 5.3B 78.69M 548M 212M 2.71B 207M 203M 8.7B
Net income -694M -918M -806M -761M -1.3B -88.01B -1.31B -9.11B -3.53B -44.96B -3.45B -3.37B -145B -736M -975M -855M -808M -1.38B -93.41B -1.39B -9.67B -3.74B -47.72B -3.66B -3.58B -153B
Net Debt -470M -622M -546M -516M -880M -59.65B -886M -6.17B -2.39B -30.48B -2.34B -2.29B -97.94B -200M -265M -233M -220M -375M -25.41B -377M -2.63B -1.02B -12.98B -995M -974M -41.72B
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
26-09-25 $15.61 -4.70% 3,807,975
26-09-24 $16.38 -0.43% 5,045,332
26-09-23 $16.45 -3.91% 3,891,072
26-09-22 $17.12 +1.30% 4,617,160
26-09-21 $16.90 -5.32% 5,780,847
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
11.79GBP
Average target price
21.61GBP
Spread / Average Target
+83.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock